Naxe as A Potential Drug Target: Unlocking Its Potential for Treatment

Target Name: NAXE

NCBI ID: G128240

NAXE

Naxe as A Potential Drug Target: Unlocking Its Potential for Treatment

Naxe (MGC119145) is a drug target (or biomarker) that has been identified in the scientific literature as having potential for use in the treatment of various diseases, including cancer, neurodegenerative disorders, and psychiatric conditions. Naxe is a protein that is expressed in various tissues throughout the body, including the brain, and has been shown to play a role in a number of important cellular processes, including cell signaling, neurotransmitter release, and stress response.

One of the key reasons for the potential of Naxe as a drug target is its involvement in the regulation of pain signaling. Pain can be a highly unpleasant sensation that can have a number of negative consequences for an organism's overall well-being. Naxe has been shown to play a role in the regulation of pain signaling in the brain, and has been shown to block the activity of a number of pain-related proteins. This suggests that Naxe could be an effective treatment for a variety of pain-related conditions, including chronic pain and neuropathic pain.

Another potential use for Naxe as a drug target is its involvement in the regulation of neurotransmitter release. Naxe has been shown to play a role in the release of neurotransmitters, such as dopamine and serotonin, from neurons in the brain. This is important for a variety of brain functions, including mood regulation, learning, and memory. Imbalances in neurotransmitter release have been implicated in a number of neuropsychiatric conditions, including depression, anxiety, and psychosis. Naxe could be an effective treatment for these conditions if it could be used to regulate neurotransmitter release in a normalized manner.

In addition to its potential role in pain and neurotransmitter regulation, Naxe has also been shown to play a role in the regulation of stress response. Stress can have a number of negative consequences on an organism's health and well-being, including an increased risk of disease and an increased risk of psychological distress. Naxe has been shown to play a role in the regulation of stress response in the brain, and has been shown to block the activity of a number of stress-related proteins. This suggests that Naxe could be an effective treatment for a variety of stress-related conditions, including anxiety and post-traumatic stress disorder.

Overall, Naxe is a protein that has the potential to be a drug target (or biomarker) for a variety of diseases. Its involvement in the regulation of pain signaling, neurotransmitter release, and stress response makes it an attractive candidate for further study and potential therapeutic use. Further research is needed to fully understand the role of Naxe in these processes and to determine its safety and effectiveness as a potential drug.

Protein Name: NAD(P)HX Epimerase

Functions: Catalyzes the epimerization of the S- and R-forms of NAD(P)HX, a damaged form of NAD(P)H that is a result of enzymatic or heat-dependent hydration. This is a prerequisite for the S-specific NAD(P)H-hydrate dehydratase to allow the repair of both epimers of NAD(P)HX. Accelerates cholesterol efflux from endothelial cells to high-density lipoprotein (HDL) and thereby regulates angiogenesis (PubMed:23719382)

The "NAXE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAXE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets